Adaptive and Automatic Insulin Pump

 

Sponsor TIFAC, Department of Science & Technology, Govt. of India/ Media Lab Asia
(Jointly with Biomedical Center, Amritapuri campus)

 

Principal Investigator

Dr.Bipin Nair
Dean - Amrita School of Biotechnology

Co-ordinator - TIFAC core in Biomedical technology

 

Summary of the project

Diabetes, which is a chronic disease caused by inherited and/or acquired deficiency in production of insulin by the pancreas, is rapidly emerging as a major health-care problem in India, especially in urban areas. According to The World Health Organization (WHO) and The International Diabetes Federation (IDF) the number of people with diabetes in India is likely to be 79.4 million by 2030. Diabetes complications include retinopathy, neuropathy, nephropathy, coronary artery disease, peripheral vascular disease etc. Studies in prominent medical journals show that intensive insulin therapy delivered with an insulin pump can help minimize the development of long-term complications such as kidney disease, impaired vision and nerve damage. Hence, most diabetic patients would prefer to use an insulin pump.

 

In spite of being a life saving device, the insulin pump is not something that is affordable to a sizeable majority of diabetic patients in India. We at Amrita can proudly boast to be the first in India to develop an efficient, but highly cost effective insulin pump that matches and/or surpasses its current international counterparts in every respect. The Amrita Insulin Pump project, funded under the Govt. of India’s TIFAC Mission Reach program and by Media Lab Asia, is designed for the precise, personalized and continuous delivery of insulin in a subcutaneous manner for the control/management of diabetes. The Amrita Biomedical Engineering Research Centre (AMBE) is committed to design and development of low cost reliable biomedical devices and implants.